Fixed-dose combination therapy for type 2 diabetes: Sitagliptin plus pioglitazone

Expert Opinion on Investigational Drugs

Volumn 19, Issue 8, 2010, Pages 1017-1025

  Bailey, Clifford J ^a   Green, Brian D ^b   Flatt, Peter R ^c  

^a ASTON UNIVERSITY   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Dipeptidyl peptidase 4 (DPP 4); Fixed dose combination (FDC); Pioglitazone; Sitagliptin; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTOPLUSMET; COMPETACT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE PLUS METFORMIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PIOGLITAZONE PLUS SITAGLIPTIN; PRANDIMET; REPAGLINIDE; SITAGLIPTIN; TANDEMACT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADD ON THERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT RESPONSE; WEIGHT GAIN; ANIMAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FEMALE; INSULIN RESISTANCE; MALE; METABOLISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; PYRAZINES; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 77954713342     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.505235     Document Type: Review

References (46)

1. International Diabetes Federation. IDF Diabetes Atlas, 4th edition. Brussels: International Diabetes Federation, 2009
2. American Diabetes Association. Position statement: standards of medical care in diabetes, 2010. Diabetes Care 2010;33(Suppl 1):S11-61
3. Liebl A, Mata M, Eschwege E.; ODE-2 Advisory board Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002;45:S23-8
4. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycaemic control improving in US adults? Diabetes Care 2008;31:81-6
5. Krentz AJ, Bailey CJ. Type 2 diabetes in practice, 2nd edition. Royal Society of Medicine Press, London; 2005
6. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008;68:2131-62
7. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009;52:17-30
8. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Practice 2007;57:455-60
9. Bailey CJ. Whence and whither the fixed-dose combination. Diabetes Vasc Dis Res 2005;2:51-3
10. Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33
11. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
12. Flatt PR, Bailey CJ, Green BD. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 2009;10:125-37
13. Merck Sharp Dohme Company report December 2008 Available from: http://google.brand.edgar-online.com/EFX-dll/EDGARpro. dllFetchFilingHtmlSection1SectionID=6289965-43085-189819&SessionID= BrEtWv7XX3-zPm7 [Last accessed 25 January 2010]
14. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004;53:2181-9
15. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 2008;13:3648-60
16. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved inretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-7
17. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
18. Aschner P, Kipnes M, Lunceford J, et al. Effect of the dipeptidyl peptidase-4 sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
19. Charbonnel B, Karisik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
20. Rosenstock J, Brazg R, Andryuk P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics 2006;28:1556-68
21. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patient with type 2 diabetes. Diabetes Care 2007;30:1979-87
22. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
23. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorder 2010;10:7 doi: 10.1186/1472-6823- 10-7
24. Chan JC, Scott R, Feriera JCA, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal failure. Diabetes Obes Metab 2008;10:545-55
25. Staels B, Fruchart J. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70
26. Sell H, Dietze-Schroeder D, Eckardt K, et al. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem Biophys Res Commun 2006;343:700-6
27. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
28. Nesto R, Bell D, Borrow RG, et al. Thiazolidinedione use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes association. Circulation 2003;108:2941-8
29. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:1885-94
30. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomised, comparator-controlled study in the US. Drug safety 2009;32:787-800
31. Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;169:1395-402
32. Maegawa H, Kashiwagi A, Tajima N, et al. Sitagliptin added to ongoing treatment with pioglitazone: study up to 52 weeks in Japanese patients with T2DM. Diabetologia 2008;51(Suppl 1):910
33. Derosa G, Maffioli P, Salvadeo SAT, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
34. Yoon KH, Shockey GR, Teng R, et al. Initial combination therapy with sitagliptin and pioglitazone improves glycemic control and measures of beta-cell function compared with pioglitazone alone in patients with type 2 diabetes. Diabetes 2009;58(Suppl 1):522
35. Yoon KH, Shockey GR, Teng R, et al. Initial combination therapy with sitagliptin and pioglitazone improves glycaemic control and measures of beta-cell function compared with pioglitazone alone in patients with type 2 diabetes. Diabetologia 2009;52;(Suppl 1):747
36. Emslie-Smith A, Dowall J, Morris A. The problem of polypharmacy in type 2 diabetes. Br J Diabetes Vasc Dis 2003;3:54-6
37. Summary of Product Characteristics-Sitagliptin. Available from: http://www.medicines.org.uk/EMC/medicine/19609/SPC/JANUVIA+100mg +film-coated+tablets/ [Last accessed 21 March 2010]
38. Summary of Product Characteristics-Pioglitazone. Available from: http://www.medicines.org.uk/EMC/medicine/4236/SPC/Actos+Tablets/ [Last accessed 21 March 2010]
39. Chapell R, Gould AL, Alexander CM. Baseline differences in A1c explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab 2009;11:1009-18
40. Williams-Herman D, Seck T, Golm H, et al. Long-term efficacy with sitagliptin as monotherapy or add-on therapy to metformin: improvement in glycaemic control over 2 years in patients with type 2 diabetes. Diabetologia 2009;52(Suppl 1):754
41. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study: a randomised clinical trial Lancet 2005;366:1279-89
42. Mu J, Petrov A, Eiermann GJ, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009;623:148-54
43. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of b-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008;10:612-25
44. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
45. Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes 2009;58(Suppl 1):2152 Available from: www.merck.com/mrl/clinical-trials/ outcomes-study.html [Last accessed 4 April 2010]
46. Bergenstal RM, Bailey CJ, Kendall DM. Therapeutic decision making in type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med 2010;123:374e9-18